#SpatialTranscriptomics reveals distinct immune and angiogenic profiles in responders and non-responders, identifying mechanisms of drug resistance. @mdanderson.bsky.social
#OpenAccess: doi.org/10.1038/s413...
#SpatialTranscriptomics reveals distinct immune and angiogenic profiles in responders and non-responders, identifying mechanisms of drug resistance. @mdanderson.bsky.social
#OpenAccess: doi.org/10.1038/s413...
By stabilizing #SIRT6 through the CAPZA1/USP48 axis, it reprograms lipid metabolism toward free cholesterol accumulation and promotes tumor progression.
#STTT #OpenAccess: doi.org/10.1038/s413...
By stabilizing #SIRT6 through the CAPZA1/USP48 axis, it reprograms lipid metabolism toward free cholesterol accumulation and promotes tumor progression.
#STTT #OpenAccess: doi.org/10.1038/s413...
in Renal Cell Carcinoma: From HIF-Mediated
Omics Remodeling to Precision Diagnostics: AbstractRenal cell carcinoma (RCC), particularly clear cell RCC
(ccRCC),
exhibits extensive metabolic, signaling, and microenvironmental remodeling
associated with… #MassSpecRSS
in Renal Cell Carcinoma: From HIF-Mediated
Omics Remodeling to Precision Diagnostics: AbstractRenal cell carcinoma (RCC), particularly clear cell RCC
(ccRCC),
exhibits extensive metabolic, signaling, and microenvironmental remodeling
associated with… #MassSpecRSS
Presented by @drchoueiri.bsky.social (@danafarber.bsky.social) at #ESMO26 @myesmo.bsky.social
More data: https://bit.ly/4e1QYhU
Presented by @drchoueiri.bsky.social (@danafarber.bsky.social) at #ESMO26 @myesmo.bsky.social
More data: https://bit.ly/4e1QYhU
OncoAlert🚨 #ESMO26 #Podium2Screen Series: XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
OncoAlert🚨 #ESMO26 #Podium2Screen Series: XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
📊 DFS HR 0.68 | 7-yr DFS 57.2% vs 44.6%
📊 OS HR 0.70 | 7-yr OS 82.3% vs 76.6%
✅ No new safety signals
Durable benefit. Standard of care confirmed.
📊 DFS HR 0.68 | 7-yr DFS 57.2% vs 44.6%
📊 OS HR 0.70 | 7-yr OS 82.3% vs 76.6%
✅ No new safety signals
Durable benefit. Standard of care confirmed.
Read the full story
#HarpswellCumberlandCounty #ME #CitizenPortal #HarpswellFireRescue #PublicSafety #HealthcareAccess
Read the full story
#HarpswellCumberlandCounty #ME #CitizenPortal #HarpswellFireRescue #PublicSafety #HealthcareAccess
Final Protocol-Prespecified Analysis of the Phase 3 KEYNOTE-564 Trial of Adjuvant Pembrolizumab Versus Placebo in Clear Cell Renal Cell Carcinoma (ccRCC)
Final Protocol-Prespecified Analysis of the Phase 3 KEYNOTE-564 Trial of Adjuvant Pembrolizumab Versus Placebo in Clear Cell Renal Cell Carcinoma (ccRCC)
tinyurl.com/msdsttrb
#glycotime
tinyurl.com/msdsttrb
#glycotime
🔹#Atezolizumab + chemo— Stage III dMMR colon cancer
🔹#Tucatinib combo— HER2+ breast cancer
🔹#Pirtobrutinib— BTK inhibitor for CLL/SLL
🔹#Belzutifan + #Lenvatinib— advanced ccRCC
🔎Discover bioactive molecules for your research: https://ow.ly/2s0R50ZWcts
🔹#Atezolizumab + chemo— Stage III dMMR colon cancer
🔹#Tucatinib combo— HER2+ breast cancer
🔹#Pirtobrutinib— BTK inhibitor for CLL/SLL
🔹#Belzutifan + #Lenvatinib— advanced ccRCC
🔎Discover bioactive molecules for your research: https://ow.ly/2s0R50ZWcts